UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

(Mark One)

 

[X]	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended December 31, 2019

 

[  ]	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from _________ to _________

 

Commission File Number: 333-187874

 

LUCKWEL PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

Nevada		46-1660653
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

 

245 First Street,Suite 1800, Cambridge, MA 02142

(Address of principal executive offices) (Zip Code)

 

(617)444 8788

(Registrant’s telephone number, including area code)

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days [X] Yes [  ] No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [  ] Yes [  ] No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	[   ]	Accelerated filer	[   ]
Non-accelerated filer	[X]	Smaller reporting company	[X]
		Emerging growth company	[X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [X] Yes [  ] No

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

 

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. [  ] Yes [  ] No

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

The number of shares of common stock, par value $0.01 outstanding as of February 13, 2020 as 143,376,000.

 

 

 

LUCKWEL PHARMACEUTICALS INC.

Form 10-Q

For the Quarter Ended December 31, 2019

 

TABLE OF CONTENTS

 

		Page
	PART I – Financial Information
Item 1:	Financial Statements	3
	Condensed Balance Sheets as of December 31, 2019 (unaudited) and March 31, 2019 (audited);	3
	Condensed Statements of Operations for the Three and Nine Months Ended December 31, 2019 and 2018 (unaudited);	4
	Condensed Statement of Changes in Stockholders’ Deficit for the Three and Nine Months Ended December 31, 2019 and 2018 (unaudited);	5
	Condensed Statements of Cash Flows for the Nine Months Ended December 31, 2019 and 2018 (unaudited);	7
	Notes to Condensed Financial Statements (unaudited).	8
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	14
Item 4:	Controls and Procedures	14
	PART II – Other Information
Item 1:	Legal Proceedings	16
Item 1A:	Risk Factors	16
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	16
Item 3:	Defaults Upon Senior Securities	16
Item 4:	Mine Safety Disclosures	16
Item 5:	Other Information	16
Item 6:	Exhibits	16
Signatures		17

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1 –FINANCIAL STATEMENTS

 

LUCKWEL PHARMACEUTICALS INC.

CONDENSED BALANCE SHEETS

 

		December 31, 2019				March 31, 2019
		(Unaudited)
Assets
Current Assets
Cash		$	33,916			$	25,754
Prepaid expense and other current assets			13,133				1,516
Total Assets		$	47,049			$	27,270
Liabilities
Current Liabilities:
Accrued liabilities		$	155,944			$	67,843
Due to officer			1,068,874				751,250
Total Liabilities			1,224,818				819,093
Stockholders’ Deficit:
Common stock, $0.01 par value; 200,000,000 shares authorized; 143,376,000 shares issued and outstanding as of December 31, 2019 and March 31, 2019, respectively			1,433,760				1,433,760
Additional paid in capital			465,748				465,748
Accumulated other comprehensive income			10				10
Accumulated deficit			(3,077,287	)			(2,691,341	)
Total stockholders’ deficit			(1,177,769	)			(791,823	)
Total Liabilities and Stockholders’ Deficit		$	47,049			$	27,270

 

The accompanying notes are an integral part of these condensed financial statements.

 

 

LUCKWEL PHARMACEUTICALS INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

		For the Three Months Ended								For the Nine Months Ended
		December 31,								December 31,
		2019				2018				2019				2018
General and administrative expenses		$	(134,045	)		$	(262,811	)		$	(385,947	)		$	(642,267	)
Other income (expense)			-				1				1				5
Net Loss		$	(134,045	)		$	(262,810	)		$	(385,946	)		$	(642,262	)
Net loss per share – basic and diluted		$	(0.001	)		$	(0.002	)		$	(0.003	)		$	(0.005	)
Weighted average common shares – basic and diluted			143,376,000				143,376,000				143,376,000				128,376,000

 

The accompanying notes are an integral part of these condensed financial statements.

 

 

LUCKWEL PHARMACEUTICALS INC.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

(Unaudited)

 

Nine Months Ended December 31, 2019

 

		Common Stock								Additional Paid-in				Accumulated other Comprehensive				Accumulated				Total Stockholders’
		Shares				Amount				Capital				Income				Deficit				Deficit
Balance as of April 1, 2019			143,376,000			$	1,433,760			$	465,748			$	10			$	(2,691,341	)		$	(791,823	)
Net loss			-				-				-				-				(385,946	)			(385,946	)
Balance as of December 31, 2019			143,376,000			$	1,433,760			$	465,748			$	10			$	(3,077,287	)		$	(1,177,769	)

 

Three Months Ended December 31, 2019

 

		Common Stock								Additional Paid-in				Accumulated other Comprehensive				Accumulated				Total Stockholders’
		Shares				Amount				Capital				Income				Deficit				Deficit
Balance as of October 1, 2019			143,376,000			$	1,433,760			$	465,748			$	10			$	(2,943,242	)		$	(1,043,724	)
Net loss			-				-				-				-				(134,045	)			(134,045	)
Balance as of December 31, 2019			143,376,000			$	1,433,760			$	465,748			$	10			$	(3,077,287	)		$	(1,177,769	)

 

The accompanying notes are an integral part of these condensed financial statements.

 

 

LUCKWEL PHARMACEUTICALS INC.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

(Unaudited)

 

Nine Months Ended December 31, 2018

 

		Common Stock								Additional Paid-in				Accumulated other Comprehensive				Accumulated				Total Stockholders’
		Shares				Amount				Capital				Income				Deficit				Deficit
Balance as of April 1, 2018			18,376,000			$	183,760			$	1,715,748			$	10			$	(2,028,815	)		$	(129,297	)
Common stock issued for service			125,000,000				1,250,000				(1,250,000	)			-				-				-
Capital distribution			-				-				-				-				(40,000	)			(40,000	)
Net loss			-				-				-				-				(642,262	)			(642,262	)
Balance as of December 31, 2018			143,376,000			$	1,433,760			$	465,748			$	10			$	(2,711,077	)		$	(811,559	)

 

Three Months Ended December 31, 2018

 

		Common Stock								Additional Paid-in				Accumulated other Comprehensive				Accumulated				Total Stockholders’
		Shares				Amount				Capital				Income				Deficit				Deficit
Balance as of October 1, 2018			143,376,000			$	1,433,760			$	465,748			$	10			$	(2,448,267	)		$	(548,749	)
Net loss			-				-				-				-				(262,810	)			(262,810	)
Balance as of December 31, 2018			143,376,000			$	1,433,760			$	465,748			$	10			$	(2,711,077	)		$	(811,559	)

 

The accompanying notes are an integral part of these condensed financial statements.

 

 

LUCKWEL PHARMACEUTICALS INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

 

		For the Nine Months Ended
		December 31,
		2019				2018
Cash Flows from Operating Activities
Net loss		$	(385,946	)		$	(642,262	)
Adjustment to reconcile net loss to net cash used in operating activities:
Prepaid expense and other current assets			(11,617	)			(569	)
Expenses paid by officer			59,024				281,019
Other payable and accrued liabilities			88,101				21,343
Net cash flow used in operating activities			(250,438	)			(340,469	)
Cash Flows from Financing Activities
Capital distribution			-				(40,000	)
Proceeds from officer loans			258,600				404,883
Net cash flow provided by financing activities			258,600				364,883
Net increase in cash			8,162				24,414
Cash, beginning of period			25,754				18,503
Cash, End of Period		$	33,916			$	42,917
Supplemental disclosures of cash flow information:
Cash paid for interest expense		$	-			$	-
Cash paid for income taxes		$	-			$	-
Noncash financing activities:
Expenses paid by officer included as loan to officer		$	59,024			$	281,019

 

The accompanying notes are an integral part of these condensed financial statements.

 

 

LUCKWEL PHARMACEUTICALS INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 1 – Organization and Description of Business

 

Luckwel Pharmaceuticals Inc. (“Luckwel” or the “Company”) plans to acquire, develop, manufacture and market pharmaceutical medication.

 

Luckycom Limited, a wholly-owned subsidiary of the Company, was incorporated in Hong Kong as Goldsans Capital (Hong Kong) Limited (“Goldsans”) on November 8, 2011. Goldsans name was changed to Wudor Capital Hong Kong Limited on May 22, 2012 and subsequently to Luckycom Limited on June 28, 2013.

 

On April 11, 2018, Luckwel filed a Certificate of Amendment to the Articles of Incorporation to change its name from Luckycom Pharmaceuticals Inc. to Luckwel and to increase the number of its authorized shares of common stock to 200,000,000 with an effective date of April 13, 2018. The Company then amended and restated its by-laws to reflect the new corporate name.

 

The Company’s corporate office is located in Waltham, Massachusetts and is incorporated in the State of Nevada.

 

As used in this Quarterly Report on Form 10-Q (“Quarterly Report”), unless otherwise indicated, all references herein to “Luckwel,” the “Company,” “we” or “us” refer to Luckwel Pharmaceuticals Inc.

 

Note 2 - Summary of Significant Accounting Policies

 

Preparation of Interim Financial Statements

 

The accompanying condensed financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial information and the Securities and Exchange Commission instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended December 31, 2019 are not necessarily indicative of the results that can be expected for the full year. The condensed financial statements contained herein should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2019 filed with the SEC on July 2, 2019.

 

These condensed financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. This assumption is presently uncertain and contingent upon the Company’s ability to raise additional working capital. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Basis of Presentation

 

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in US dollars (“USD”).

 

Cash

 

Cash includes all cash in bank with no restrictions. The Company had $33,916 and $25,754 of cash as of December 31, 2019 and March 31, 2019, respectively.

 

 

LUCKWEL PHARMACEUTICALS INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 2 – Summary of Significant Accounting Policies (Continued)

 

Fair Value of Financial Instruments

 

Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement, defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

 

The Company’s financial instruments consist of cash, accrued liabilities and due to officer. The carrying amount of these financial instruments approximate fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. There were no financial instruments classified as Level 3 in the fair value hierarchy during the three and nine months ended December 31, 2019 and December 31, 2018, respectively.

 

Income Taxes

 

During the three and nine months ended December 31, 2019 and 2018, there was no provision for income taxes as the Company incurred losses during both periods. Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

 

Uncertain Tax Positions

 

The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. Interest and penalties related to uncertain tax positions are recognized and recorded as necessary in the provision for income taxes. Tax years from 2013 forward remain open to examination by the U.S. federal tax authority due to the carryover of net operating losses or tax credits. According to Hong Kong Inland Revenue Department, the statute of limitation is six years if any company chargeable with tax has not been assessed at less than the proper amount. The statute of limitation is extended to 10 years if the underpayment of taxes is due to fraud or willful evasion. There were no uncertain tax positions as of December 31, 2019 and March 31, 2019.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Basic and Diluted Net Loss Per Share

 

Basic loss per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted loss per share is calculated by dividing the Company’s net loss available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There were no potentially dilutive debt or equity outstanding as of December 31, 2019 and March 31, 2019, respectively.

 

Recent Accounting Pronouncements

 

The Company does not believe any recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the financial position, statements of operations and cash flows.

 

 

LUCKWEL PHARMACEUTICALS INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 3 – Going Concern

 

The Company does not have any sources of revenues and needs additional cash resources to maintain its operations. The Company has $33,916 in cash and a stockholders’ deficit of $1,177,769, has incurred losses since inception of $3,077,287, and has not yet received any revenue from sales of products or services. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital or obtain necessary debt financing. The Company is presently dependent on its Chief Executive Officer, Mr. Kingrich Lee to either provide the Company funding for its daily operation and expenses, including professional fees and fees charged by regulators, although he is under no obligation to do so, or to spearhead financing efforts with third parties.

 

The Company currently does not have any arrangements in place to complete any financings and there is no assurance that it will be successful in completing any such financings on terms that will be acceptable.

 

The Company’s priority, should it receive such additional funds, is to pay its legal, accounting and its filing obligations under United States federal securities laws, as well as to pay its other accounts payable generated in the ordinary course of business.

 

The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses and further losses are anticipated as a result of the development of business which raises substantial doubt about its ability to continue as a going concern within the next twelve months from the issuance date of the financial statements. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining financing necessary to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and/or private placement of its common stock.

 

 

LUCKWEL PHARMACEUTICALS INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 4 – Related Party Transactions

 

The Company’s sole officer and director, and a shareholder, Mr. Kingrich Lee, loaned an aggregate of $258,600 in cash and made payments aggregating $59,024 on behalf of the Company during the nine months ended December 31, 2019. During the comparable period of 2018, he loaned an aggregate of $404,883 in cash and made aggregate payments of $281,019 on behalf of the Company.

 

Accordingly, Mr. Kingrich Lee is owed an aggregate amount of $1,068,874 and $751,250 as of December 31, 2019 and March 31, 2019, respectively, from the Company.

 

The amounts are unsecured, non-interest bearing and are due on demand.

 

On May 3, 2018, the Company entered into an Intellectual Property Sale and Purchase Agreement (the “Agreement”) with Luckwel Asia Limited (the “Seller”, formerly known as Essential Choice Ventures Ltd), an entity under common control of Mr. Kingrich Lee to purchase from the Seller the intellectual property rights to five drugs, comprising three generic medicines used to treat hypertension and high cholesterol and two advanced drug candidates - KL008 for treatment of hypertension and KL009 for treatment of high cholesterol in various stages of being developed and manufactured (the “Transaction”). Pursuant to the terms of the Agreement, the Company agreed to pay the Seller on closing (i) $40,000 and (ii) issue an aggregate 125,000,000 restricted shares of its common stock, par value $0.01. The Transaction closed on May 3, 2018. The Company recorded the carrying value of the intellectual property as nil in the Seller’s record, $40,000 as capital distribution to the Seller and recorded the par value of the common stock as additional paid-in capital, which was due to the Transaction being regarded as an equity transaction because both parties were under common control.

 

On November 1, 2017, the Company entered into an employment agreement with Mr. Kingrich Lee. The agreement is for one year, renewable for successive one-year terms if not terminated, and provides an annual compensation of $180,000, and other benefits, including housing and education allowances. On November 1, 2019, the Company renewed the employment agreement with Mr. Kingrich Lee for another one-year term. As of December 31, 2019, Mr. Kingrich Lee was owed $90,000 pursuant to his employment agreement, which is recorded in accrued expenses.

 

Note 5 – Capital Stock

 

As of December 31, 2019 and 2018, the Company had 143,376,000 shares of common stock issued and outstanding. During the nine months ended December 31, 2018, the Company issued an aggregate of 125,000,000 restricted shares of its common stock to Luckwel Asia Limited.

 

Note 6 – Subsequent Events

 

On January 27, 2020, the Company received a loan of $27,000 from its’ sole officer and director, and a shareholder, Mr. Kingrich Lee. The loan is non-interest bearing and due on demand.

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

 

Overview

 

We are presently still a shell company and have not begun operations. As reflected in the accompanying condensed financial statements we have no sources of revenue and need additional cash resources to maintain our operations. At December 31, 2019, we had $33,916 in cash and a stockholders’ deficit of $1,177,769, had incurred losses since inception of $3,077,287, and had not yet received any revenue from sales of products or services. These factors raise substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent on our ability to raise additional capital or obtain necessary debt financing. We are presently dependent on our Chief Executive Officer, Mr. Kingrich Lee, to either provide us funding for its daily operation and expenses, including professional fee and fees charged by regulators, although he is under no obligation to do so, or to spearhead financing efforts with third parties.

 

We currently do not have any arrangements in place to complete any financings and there is no assurance that we will be successful in completing any such financings on terms that will be acceptable.

 

Our priority, should we receive such additional funds, is to pay our legal, accounting and other fees associated with our Company and our filing obligations under United States federal securities laws, as well as to pay our other accounts payable generated in the ordinary course of business.

 

Once these costs are accounted for, we will focus on the following activities:

 

1.	Establish a management team by March 2020 to work on establishing pharmaceutical operations in Boston focusing on:
	LWEL-1807 (previously referred to as “KL-007”), a pipeline drug for treatment of malaria.
	LWEL-1808 (previously referred to as “KL-008”), a pipeline drug for the treatment of certain leukemias.
	LWEL-1809 (previously referred to as “KL-009”), a pipeline drug for treating rheumatoid arthritis/pain.
2.	Commence registration of  intellectual property by March 2020.
3.	Launch generic oncological drugs in Asia by June 2020.

 

Any failure to raise money will have the effect of delaying the timeframes in our business plan as set forth above, and we may have to push back the dates of such activities or might not be able to undertake such activities at all.

 

 

Results of Operations

 

Three and Nine Months Ended December 31, 2019 and 2018

 

Operating Revenue

 

We recorded no revenue for the three and nine months ended December 31, 2019 and December 31, 2018, as we are a shell company without any operations to generate revenue.

 

Operating Expenses

 

We had operating expenses of $134,045 and $262,811 for the three months ended December 31, 2019 and 2018, respectively, and $385,947 and $642,267 for the nine months ended December 31, 2019 and 2018, respectively.

 

Our operating expenses for the three months ended December 31, 2019 consisted mainly of professional fees of $49,658, officer compensation of $73,046 and travel expenses of $6,803, rent of $1,608, and office operations expenses of $2,931. Operating expenses decreased significantly from the comparable prior period because we attended fewer conferences and meetings and spent less on office expenses.

 

Our operating expenses for the three months ended December 31, 2018 consisted mainly of professional fees of $108,320, officer compensation of $60,488, travel and entertainment expenses of $47,805, rent of $959 and office operation expenses of $45,240.

 

Our operating expenses for the nine months ended December 31, 2019 consisted mainly of professional fees of $134,064, officer compensation of $213,261, travel expenses of $24,559, rent of $4,468, office operations expenses of $7,822 and other operation expenses of $1,773.

 

Our operating expenses for the nine months ended December 31, 2018 consisted mainly of professional fees of $209,735, officer compensation of $206,201, travel expenses of $80,502, rent of $2,426, office operations expenses of $142,900 and other operation expenses of $503.

 

We anticipate our operating expenses will increase significantly as we proceed to implement our business plan described above and become operational.

 

Net Loss

 

We incurred a net loss of $134,045 and $262,810 for the three months ended December 31, 2019 and 2018, respectively, and a net loss of $385,946 and $642,262 for the nine months ended December 31, 2019 and 2018, respectively.

 

Liquidity and Capital Resources

 

As of December 31, 2019, we had $47,049 in current assets, consisting of $33,916 in cash and $13,133 in prepaid expense and other current assets, and current liabilities in the amount of $1,224,818, consisting of accrued liabilities of $155,944, and $1,068,874 due to an officer. We had a stockholders’ deficit of $1,177,769 as of December 31, 2019.

 

The table below sets forth selected cash flow data for the periods presented:

 

		Nine Months Ended
		December 31
		2019				2018
Net cash used in operating activities		$	(250,438	)		$	(340,469	)
Net cash provided by financing activities			258,600				364,883
Net increase in cash		$	8,162			$	24,414

 

 

Our negative operating cash flows were a result of operating expenses and no revenue.

 

Our positive financing cash flows were a result of proceeds from officer loans.

 

On November 1, 2017, the Company entered into an employment agreement with Mr. Kingrich Lee. The agreement is for one year, renewable for successive one-year terms if not terminated, and provides an annual compensation of $180,000, and other benefits, including housing and education allowances. On November 1, 2019, the Company renewed the employment agreement with Mr. Kingrich Lee for another one-year term. This agreement will materially impact our cash needs in the future, as any investment money we obtain will be used to pay Mr. Kingrich Lee’s salary and other benefits, and will have the effect of diverting funds that may be used to pursue our business plan.

 

We had $33,916 in cash as of December 31, 2019, which is insufficient to operate our business at the current level for the next 12 months from the issuance date of this report and insufficient cash to achieve our business goals. The success of our business plan beyond the next 12 months from the issuance date of this report is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sale of stock or the advancement of loans of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Not required for smaller reporting companies.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

We conducted an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of December 31, 2019, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer has concluded that as of December 31, 2019, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified below.

 

 

Our Chief Executive Officer and Chief Financial Officer does not expect that our disclosure controls or internal controls will prevent all error and all fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2019 based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of December 31, 2019, our internal controls over financial reporting were not effective. The material weaknesses identified related to (i) a lack of accounting staff and resources with appropriate knowledge of U.S. GAAP and SEC reporting and compliance requirements; (ii) a lack of sufficient documented financial closing policies and procedures; and (iii) a lack of independent directors and an audit committee.

 

We plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we hope to implement the following changes during our fiscal year ending March 31, 2020: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopt sufficient written policies and procedures for accounting and financial reporting, and (iii) strengthen our financial team by employing more qualified accountant(s) conversant with U.S. GAAP to enhance the quality of our financial reporting function. The remediation efforts set out in (i), (ii) and (iii) are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

 

Changes in Internal Control over Financial Reporting

 

During the quarter ended December 31, 2019, there have been no changes in our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

 

Item 1A. Risk Factors

 

Not required for smaller reporting companies.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

Exhibit Number		Description of Exhibit
31.1*		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		XBRL Instance Document
101.SCH*		XBRL Taxonomy Extension Schema Document
101.CAL*		XBRL Taxonomy Calculation Linkbase Document
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		XBRL Taxonomy Label Linkbase Document
101.PRE*		XBRL Taxonomy Presentation Linkbase Document

 

* Filed herewith

**Furnished herewith

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Luckwel Pharmaceuticals Inc.
Date:	February 13, 2020
By:	/s/ Kingrich Lee
	Kingrich Lee
Title:	Chief Executive Officer and Chief
	Financial Officer (Principal Executive Officer and Principal Accounting and Financial Officer)